Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium is deficient, so the mucus contains less water and its viscosity is abnormally increased. Moli1901 corrects the abnormal transport of chloride ans water in the lungs thereby reducing the formation of mucus plugs and improving clearance.
Conditions
Sponsors
AOP Orphan Pharmaceuticals AG
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 16 years of age or older (Phase I of Study) resp. 12 years of age or older (Phase II of Study). Have a confirmed diagnosis of cystic fibrosis [positive sweat chloride value > 60 mEq/l (by quantitative pilocarpine iontophoresis) and/or genotype with two identifiable mutations consistent with CF, accompanied by one or more clinical features consistent with the CF phenotype. Have Screening FEV1 greater than 60% of predicted. Have oxygen saturation level measured by pulse oximetry (Sp02) > 90 % on room air. Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Have a pulmonary disease such as pneumonia, tuberculosis, or lung cancer. Have had an acute upper respiratory tract infection within 2 weeks of screening. Have had an acute lower respiratory tract infection (requiring antibiotics or hospitalization) within 4 weeks of screening. Have had an exacerbation within 4 weeks of screening. Are on a tobramycin “on-off” treatment Receive parenteral antibiotics via “on-off” treatment. Have any clinically significant liver, renal, cardiac, neurologic, or hematologic disease. Have Burkholderia cepacia or allergic bronchopulmonary aspergillosis. Have smoked more than 3 cigarettes per day within the past 12 months. Have a history of alcohol (> 40g/d) or drug abuse. Have participated in an investigational drug study within 4 weeks of screening. Show bronchial hyperresponsiveness. Do not have stable lung function, i.e. have more than 10% FEV1 variation in the last 3 months before treatment starts. Are women of child bearing potential and refuse to use effective contraception or are pregnant or lactating.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The study objective is to determine safety and tolerability of a multiple-dose regimens of aerosolized Moli1901 in adolescents (12 years of age or older) and adults with cystic fibrosis and mild to moderate lung disease.;Secondary Objective: ;Primary end point(s): •Safety and tolerability will be assessed by evaluating general physical condition, adverse events, changes in pulmonary function test results, pulse oximetry, vital signs, physical examinations, ECGs (electrocardiograms), and clinical laboratory tests. Pulmonary function evaluation will focus on pre-treatment and post-treatment pulmonary function test results as demonstrated by FEV1 (Forced Expiratory Volume in One Second), FVC (Forced Vital Capacity), and FEF25-75 (Forced Expiratory Flow 25–75% of FVC). •Exercise tolerance will be assessed based on evidence of either improvement or worsening. •Quality of life will be assessed using a questionnaire to be filled out by the study subjects at Study Start and end of treatment phase and at Study End | — |
Countries
Hungary
Outcome results
None listed